Plain-English translation of NCT06560528 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether Disitamab Vedotin, when combined with two other medications called Tislelizumab and Capecitabine, can help people with advanced stomach cancer or cancer at the junction of the stomach and esophagus. The treatment is given in two phases: first before surgery (to shrink the tumor) and then after surgery (to prevent the cancer from returning). All participants must have a specific marker on their cancer cells called HER2 overexpression.
Currently, doctors don't have many treatment options specifically designed for stomach cancers with HER2 overexpression before and after surgery. This trial is testing whether this new three-drug combination can improve survival and outcomes in people with this particular type of advanced stomach cancer.
You likely qualify if…
You likely don't qualify if…
You would receive the three-drug combination treatment in two phases. First, you'll get 3 cycles of the medication before surgery (each cycle is 3 weeks), then you'll have the surgery to remove the tumor. After recovering from surgery, you'll receive 5 more cycles of the same medication over approximately 15 weeks. During treatment, you'll have regular visits to the hospital or clinic for the medications and to check for side effects. The study involves about 40 people total and is currently recruiting new participants.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China